Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CorMedix Inc (CRMD : NSDQ)

• Company Description    CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog Number of Employees: 191

• Price / Volume Information    Yesterday's Closing Price: $7.98 Daily Weekly Monthly 20 Day Moving Average: 1,397,344 shares Shares Outstanding: 78.45 (millions) Market Capitalization: $626.05 (millions) Beta: 1.46 52 Week High: $17.43 52 Week Low: $6.13 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.87% 3.55% 12 Week 8.57% 0.37% Year To Date -31.38% -36.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 389 INTERPACE PKWY SUITE 450 - PARSIPPANY,NJ 07054 USA ph: 908-517-9500 fax: 908-429-4307 daniel@lifesciadvisors.com http://www.cormedix.com

• General Corporate Information    Officers Joseph Todisco - Chief Executive Officer; Director and Chairman of Susan Blum - Executive Vice President and Chief Financial Offic Myron Kaplan - Director Janet Dillione - Director Gregory Duncan - Director Peer Information CorMedix Inc (CORR.) CorMedix Inc (RSPI) CorMedix Inc (CGXP) CorMedix Inc (BGEN) CorMedix Inc (GTBP) CorMedix Inc (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 21900C308 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 78.45 Most Recent Split Date: 3.00 (0.20:1) Beta: 1.46 Market Capitalization: $626.05 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.25 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.47 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: 17.10 Trailing 12 Months: 4.22 PEG Ratio: - Price Ratios Price/Book: 1.43 Price/Cash Flow: 3.90 Price / Sales: 1.56 EPS Growth vs. Year Ago Period: 43.33% vs. Previous Quarter: -29.51% Sales Growth vs. Year Ago Period: 226.05% vs. Previous Quarter: -0.92% ROE 03/31/26 - 45.57 12/31/25 - 52.30 09/30/25 - 51.77 ROA 03/31/26 - 24.76 12/31/25 - 29.46 09/30/25 - 32.33 Current Ratio 03/31/26 - 2.97 12/31/25 - 2.11 09/30/25 - 1.94 Quick Ratio 03/31/26 - 2.74 12/31/25 - 1.94 09/30/25 - 1.73 Operating Margin 03/31/26 - 40.93 12/31/25 - 46.77 09/30/25 - 47.97 Net Margin 03/31/26 - 45.25 12/31/25 - 52.31 09/30/25 - 75.83 Pre-Tax Margin 03/31/26 - 46.25 12/31/25 - 48.13 09/30/25 - 49.94 Book Value 03/31/26 - 5.57 12/31/25 - 5.14 09/30/25 - 4.78 Inventory Turnover 03/31/26 - 2.29 12/31/25 - 1.90 09/30/25 - 1.18 Debt-to-Equity 03/31/26 - 0.33 12/31/25 - 0.36 09/30/25 - 0.39 Debt-to-Capital 03/31/26 - 24.90 12/31/25 - 26.38 09/30/25 - 27.94

Powered by Zacks Investment Research ©